Carbidopa And Levodopa
NDC 43353-327
Product Information
Carbidopa And Levodopa is a ANDA-approved product labeled by Aphena Pharma Solutions - Tennessee, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a purple product. This product entry covers the primary NDC 43353-327 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
MYLAN;88
Code Structure Chart
Product Details
What is NDC 43353-327?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CARBIDOPA (UNII: MNX7R8C5VO)
- CARBIDOPA ANHYDROUS (UNII: KR87B45RGH) (Active Moiety)
- LEVODOPA (UNII: 46627O600J)
- LEVODOPA (UNII: 46627O600J) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 308988 - carbidopa 25 MG / levodopa 100 MG Extended Release Oral Tablet
- RxCUI: 308988 - carbidopa (as carbidopa monohydrate) 25 MG / levodopa 100 MG Extended Release Oral Tablet
- RxCUI: 308988 - Carbidopa 25 MG / L-DOPA 100 MG Extended Release Oral Tablet
* Please review the full disclaimer at the bottom of this page.
Patient Education
Levodopa and Carbidopa
The combination of levodopa and carbidopa is used to treat the symptoms of Parkinson's disease and Parkinson's-like symptoms that may develop after encephalitis (swelling of the brain) or injury to the nervous system caused by carbon monoxide poisoning or manganese poisoning. Parkinson's symptoms, including tremors (shaking), stiffness, and slowness of movement, are caused by a lack of dopamine, a natural substance usually found in the brain. Levodopa is in a class of medications called central nervous system agents. It works by being converted to dopamine in the brain. Carbidopa is in a class of medications called decarboxylase inhibitors. It works by preventing levodopa from being broken down before it reaches the brain. This allows for a lower dose of levodopa, which causes less nausea and vomiting.
[Learn More]
* Please review the full disclaimer at the bottom of this page.